<scp>ApoE4</scp> Upregulates <scp>GSK</scp>‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice
Our findings suggest that ApoE4 exacerbates AD pathogenesis by activating GSK-3β. Furthermore, targeting GSK-3β may offer a promising therapeutic strategy to halt the progression from T2DM to AD, providing new insights into potential interventions for patients at risk.
Authors
- Haibo Xu (ORCID: https://orcid.org/0000-0002-8451-8979)
- Yang Gao (ORCID: https://orcid.org/0000-0003-1707-9053)
- Zhipeng Xu (ORCID: https://orcid.org/0000-0002-2048-3789)
- Jiazhao Xie
- Fei Sun (ORCID: https://orcid.org/0000-0001-8184-6718)
- Fuqiang Zhang
- Xin Wang (ORCID: https://orcid.org/0000-0001-7440-3150)
- Yao Zhang (ORCID: https://orcid.org/0000-0001-9314-5820)
- Jian–Zhi Wang
- Yarong Wang (ORCID: https://orcid.org/0000-0002-0551-5412)
- Junjian Zhang (ORCID: https://orcid.org/0000-0002-4557-5137)
- Yuying Wang
Institutions
- Nantong University (CN)
- Jianghan University (CN)
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/cns.70575
- Citations
- 3
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation